Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation.
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 31 Aug 2018 Biomarkers information updated
- 12 Mar 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 04 Sep 2013 New trial record